hu1124 en es it fr

hu1124 Brand names, hu1124 Analogs

hu1124 Brand Names Mixture

  • No information avaliable

hu1124 Chemical_Formula

No information avaliable

hu1124 RX_link

hu1124 fda sheet

hu1124 msds (material safety sheet)

hu1124 Synthesis Reference

sequence listed in Werther WA, Gonzalez TN, O'Connor SJ, McCabe S, Chan B, Hotaling T, Champe M, Fox JA, Jardieu PM, Berman PW, Presta LG. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996 Dec 1;157(11):4986-95

hu1124 Molecular Weight

No information avaliable

hu1124 Melting Point

61 oC (FAB fragment), 71 oC (whole mAb)-Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000).

hu1124 H2O Solubility

No information avaliable

hu1124 State


hu1124 LogP

No information avaliable

hu1124 Dosage Forms

Solution (Subcutaneous Injection)

hu1124 Indication

For treatment of psoriasis

hu1124 Pharmacology

Lymphocyte activation and trafficking to skin play a role in the pathophysiology of chronic plaque psoriasis. In psoriatic skin, ICAM-1 cell surface expression is upregulated on endothelium and keratinocytes. Raptiva inhibits the binding of LFA-1 to the intercellular adhesion molecule-1 (ICAM-1), thereby inhibiting the adhesion of leukocytes to other cell types.

hu1124 Absorption

No information avaliable

hu1124 side effects and Toxicity

No information avaliable

hu1124 Patient Information


hu1124 Organisms Affected

Humans and other mammals